Bruehlman Ronald E
Bruehlman Ronald E's purchase track record
Bruehlman Ronald E has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/23/2021 | IQV | $1K | +6.0% | -14.4% | +1.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
IQVIA Expands Veeva Partnership and Raises Price Targets. IQVIA announced an expanded partnership with Veeva Systems to use clinical operations software across its development studies. This move coincides with reports of an improving demand environment and high win rates. Stifel recently raised its price target for the stock to $303, reflecting confidence in the company's backlog and operational updates.
Transaction History
| GDRX | ▲ Buy | Grant | 73,434 | $0 | 6/16/2026 | View on chart |
| GDRX | ▲ Buy | Grant | 4,642 | $0 | 5/27/2026 | View on chart |
| IQV | ▲ Buy | Grant | 16,335 | $0 | 2/8/2026 | View on chart |
| IQV | ▼ Sell | Tax Withholding | 6,801 | $1.3M | 2/8/2026 | View on chart |
| GDRX | ▲ Buy | Grant | 18,251 | $0 | 1/1/2026 | View on chart |
| GDRX | ▲ Buy | Option Exercise | 21,691 | — | 11/8/2025 | View on chart |
| GDRX | ▲ Buy | Grant | 57,050 | $0 | 6/3/2025 | View on chart |
| IQV | ▼ Sell | Tax Withholding | 907 | $188K | 2/10/2025 | View on chart |
| IQV | ▲ Buy | Grant | 6,286 | $0 | 1/28/2025 | View on chart |
| IQV | ▼ Sell | Tax Withholding | 2,201 | $448K | 1/28/2025 | View on chart |
| GDRX | ▲ Buy | Grant | 10,653 | $0 | 1/1/2025 | View on chart |
| GDRX | ▲ Buy | Grant | 1,128 | $0 | 11/8/2024 | View on chart |
| GDRX | ▲ Buy | Grant | 20,503 | $0 | 11/8/2024 | View on chart |
| IQV | ▼ Sell | Tax Withholding | 907 | $198K | 2/10/2024 | View on chart |
| IQV | ▼ Sell | Tax Withholding | 1,033 | $225K | 2/9/2024 | View on chart |
| IQV | ▲ Buy | Grant | 24,141 | $0 | 2/6/2024 | View on chart |
| IQV | ▼ Sell | Tax Withholding | 10,514 | $2.3M | 2/6/2024 | View on chart |
| IQV | ▼ Sell | Tax Withholding | 2,588 | $560K | 8/3/2023 | View on chart |
| IQV | ▼ Sell | Tax Withholding | 614 | $137K | 2/10/2023 | View on chart |
| IQV | ▼ Sell | Tax Withholding | 717 | $165K | 2/9/2023 | View on chart |
| IQV | ▼ Sell | Tax Withholding | 2,588 | $604K | 8/3/2022 | View on chart |
| IQV | ▲ Buy | Grant | 5,869 | $0 | 2/10/2022 | View on chart |
| IQV | ▼ Sell | Tax Withholding | 705 | $180K | 2/9/2022 | View on chart |
| IQV | ▼ Sell | Open Market | 4 | $1K | 10/25/2021 | View on chart |
| IQV | ▲ Buy | Open Market | 4 | $1K | 9/23/2021 | View on chart |
| IQV | ▲ Buy | Open Market | 13 | $3K | 7/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
GoodRx Expands Savings Offering With Companion Family Plan for Pets and People
GoodRx has launched a Companion Family Plan that extends its healthcare savings to pets as well as household members. The company is positioning the new offering as a way to bring prescription and care discounts to the entire family, including animals, broadening the appeal of its platform. Separately, a recent market analysis listed GoodRx among stocks viewed as having mixed momentum. The company is already trading near a well-tested support level, providing some technical context around the announcement.
GoodRx Expands Savings Offering With Companion Family Plan for Pets and People. GoodRx has launched a Companion Family Plan that extends its healthcare savings to pets as well as household members. The company is positioning the new offering as a way to bring prescription and care discounts to the entire family, including animals, broadening the appeal of its platform. Separately, a recent market analysis listed GoodRx among stocks viewed as having mixed momentum. The company is already trading near a well-tested support level, providing some technical context around the announcement.